Searchable abstracts of presentations at key conferences in endocrinology
Previous issue | Volume 101 | ETA2024 | Next issue

46th Annual Meeting of the European Thyroid Association (ETA) 2024

Oral Presentations

Oral Session 3: Young Investigators/Clinical and Translational

ea0101op-03-01 | Oral Session 3: Young Investigators/Clinical and Translational | ETA2024

Impact of reclassification of oncocytic and follicular thyroid carcinoma by the 2022 who classification

Stegenga Merel , Oudijk Lindsey , Van Velsen Evert , Medici Marco , Verburg Frederik , Van Ginhoven Tessa , Peeters Robin , van Kemenade Folkert , Edward Visser W.

Introduction: The 2022 WHO Classification categorizes oncocytic (OTC) and follicular thyroid carcinoma (FTC) based on the degree of capsular and vascular invasion into minimally invasive (MI), encapsulated angioinvasive (EA) and widely invasive tumors (WI). While associations with clinical outcomes have extensively been studied in FTC, for OTC robust clinical data is lacking. The aim of this study is to investigate the newly defined categorization by the 2022 WHO Classificatio...

ea0101op-03-02 | Oral Session 3: Young Investigators/Clinical and Translational | ETA2024

Impact of physical activity and its maintenance in the efficacy and safety of tyrosine kinase inhibitors in advanced thyroid carcinoma patients

Ceruti Daniele , De Leo Simone , Cervellini Fabrizio , Succi Massimiliano , Trevisan Matteo , Lugaresi Marina , Moneta Claudia , Fugazzola Laura , Colombo Carla

Background: Tyrosine kinase inhibitors (TKIs) have been shown to improve progression-free survival (PFS) in advanced thyroid cancer (TC), though their administration is burdened by multiple adverse events (AEs). Maintaining optimal drug dosage for optimal tumour response can be challenging and prehabilitation, aiming to improve patient well-being before cancer treatment, is becoming relevant in this context. While some information exists for other cancers, no data are availabl...

ea0101op-03-03 | Oral Session 3: Young Investigators/Clinical and Translational | ETA2024

Effects of tocilizumab treatment in corticosteroid-resistant graves’ orbitopathy

Rymuza Joanna , Kuś Aleksander , Białas-Niedziela Dorota , Turczyńska Monika , Kęcik Dariusz , Bednarczuk Tomasz

Introduction: Treatment of GravesÂ’ Orbitopathy (GO) remains a challenge. Approximately 20-30% of patients show resistance or incomplete response to high-dose glucocorticoid therapy. According to current guidelines the use of tocilizumab (TCZ), a monoclonal antibody against IL6 receptor, has been proposed as one of the second-line therapies.Objectives: Our aim was to assess the efficacy and safety of TCZ treatment in patients with glucocorticoid-resi...

ea0101op-03-04 | Oral Session 3: Young Investigators/Clinical and Translational | ETA2024

T3 analogue triiodothyroacetic acid (TRIAC) treatment and survival in MCT8 deficiency: an international real-world cohort study

van der Most Floor , Edward Visser W. , Chaker Layal , Labrecque Jeremy , Freund Matthijs , van Geest Ferdy , Groeneweg Stefan , van der LInden Barbara

Objectives: MCT8 deficiency results from a rare X-linked genetic defect in the thyroid hormone monocarboxylate transporter (MCT) 8. MCT8 deficiency is characterized by severe neurocognitive disabilities and peripheral thyrotoxicosis. Mortality rates in MCT8 deficiency are high with 30% dying during childhood. The T3 analogue triiodothyroacetic acid (Triac) has been proven to safely alleviate peripheral thyrotoxicosis in patients with MCT8 deficiency. As thyrotoxicosis is linke...

ea0101op-03-05 | Oral Session 3: Young Investigators/Clinical and Translational | ETA2024

Predictors of disease progression in patients with suspicious lymph nodes after initial treatment for thyroid carcinoma

De Luca Alessia , Trevisan Matteo , Moneta Claudia , Colombo Carla , Gazzano Giacomo , Dionigi Gianlorenzo , Fugazzola Laura , de Leo Simone

Objective: The clinical course of metastatic lymph nodes in patients with differentiated thyroid cancer is unclear, due to the lack of universal criteria defining disease progression. The aim of the present study was to evaluate the characteristics of suspicious lymph nodes in patients with differentiated thyroid cancer, in order to distinguish lesions with an indolent behaviour and to identify potential predictors of disease progression.Methods: We retr...

ea0101op-03-06 | Oral Session 3: Young Investigators/Clinical and Translational | ETA2024

The association of maternal thyroid function with offspring iq and brain morphology: persistency into early adolescence and relevance of tpoab positivity

Osinga Joris , Mulder Tessa , Peeters Robin , Tiemeier Henning , Muetzel Ryan , Korevaar Tim

Background: Maternal thyroid hormones regulate neurodevelopment of the fetus. Maternal thyroid dysfunction has been associated with lower offspring IQ and alterations in brain morphology in early childhood, but it remains unknown if these associations persist as development progresses.Methods: We performed a prospective cohort study including participants from an ongoing birth cohort in Rotterdam, the Netherlands, with data on gestational thyroid functio...